正邦科技(002157.SZ):2022年擬獲控股股東及其一致行動人提供借款不超50億元
格隆匯12月27日丨正邦科技(002157.SZ)公佈,2021年12月27日,公司第六屆董事會第三十四次會議,審議通過了《關於2022年向控股股東及其一致行動人借款暨關聯交易的議案》,同意公司向控股股東正邦集團有限公司(“正邦集團”)及其一致行動人江西永聯農業控股有限公司(“江西永聯”)申請借款,借款總金額不超過50億元人民幣(含),用於滿足短期內、臨時性補充公司流動資金和歸還銀行貸款需求,借款利率為同期銀行貸款利率,借款額度有效期為自股東大會審議通過後12個月,額度在有效期內可循環使用。
同日,公司與正邦集團、江西永聯在江西省南昌市簽訂了《借款協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.